Efficacy of Zinc L-carnosine in Maintaining Remission of Gastroesophageal Reflux Disease
Status:
Unknown status
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
Gastroesophageal reflux disease (GERD), according to the Montreal classification, is defined
as a condition that develops when the reflux of stomach contents causes troublesome symptoms
and/or complications. GERD, as clinically defined by the presence of heartburn, acid
regurgitation, or both, at least once a week, is a global disease, being one of the most
common gastroenterological disorders worldwide that affects roughly 10-30% of the general
population in the Western world and less than 10% of the Asian populations. GERD
complications may be life threatening and range from reflux esophagitis to Barrett's
oesophagus and, eventually, adenocarcinoma.
Zinc L-carnosine (brand name in Italy: Hepilor®) is a chelate compound of zinc and
L-carnosine, with a long history of more than 20 years of clinical use in Japan that has
recently become available in Italy for the treatment of any condition that requires a mucosal
protection and mucosal repair within the gastrointestinal tract, thus including GERD.
However, clinical data in western countries are limited. The aim of this double-blind,
placebo-controlled study is to demonstrate the efficacy of Zinc-l-carnosine in maintaining
GERD clinical remission during a 12-week treatment.